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Introduction 
Nonsteroidal anti-inflammatory drugs (NSAIDs) are medications used to treat 
inflammation, mild pain, and fever.  This class of drugs is commonly prescribed as treatment for 
chronic pain, dental pain, dysmenorrhea, gout, headache, tendonitis, bursitis, rheumatoid 
arthritis, and osteoarthritis (Vieson, 2003).  NSAIDs work by inhibiting the synthesis of 
prostaglandins, which promote inflammation and pain.  These drugs are among the most widely 
prescribed medications, generating between 35 and 70 million prescriptions in the United States 
per year, while the world market for NSAIDs is reported to be a $6 billion per year industry 
(Bruno & Carter, 2004). 
NSAIDs have commonly been exploited for their analgesic and anti-inflammatory 
properties in the treatment of exercise-induced muscle injury.  Exercise-induced muscle injury is 
a common problem in sports and in the workplace (Mishra, Friden, Schmitz, & Lieber, 1995).   
These injuries are primarily due to eccentric contractions of the muscle and cause the release of 
enzyme muscle markers into circulation.  In order for the muscle to be repaired after an injury, 
satellite cells must become activated and inflammatory mediators mobilized to the injured 
muscle (McArdle, Katch, & Katch, 2001). 
Since acute inflammation initiates repair in muscle tissue, research has been conducted to 
study the effects of NSAIDs in anti-inflammatory doses on muscle recovery and strength.  The 
studies employ different methods of eccentric contraction-inducing muscle injury and utilize 
several different NSAIDs after injury.  Each study has evaluated different markers of muscle 
injury and recovery and the effect that NSAIDs have on these markers after injury.  Research has 
primarily focused on recovery of the muscle cell histologically, influx of inflammatory   2
mediators, satellite cell proliferation, delayed onset muscle soreness (DOMS), and force 
generation after muscle injury.   
Due to the increasing use of NSAIDs, it is imperative to determine if NSAID inhibition 
of inflammation is delaying muscle from repairing itself after injury. If present, this process is 
then leading to subsequent delay of muscle recovery and regeneration of muscle strength.  
Individual studies examining the use of NSAIDs after eccentric contraction-induced muscle 
injury have shown either no measurable consequence, a definitive support of, or evidence against 
this common utilization.  This review of the literature examines each individual study and 
attempts to come to a conclusion regarding this controversial topic.   3
NSAIDs 
The use of NSAIDs to alleviate the signs and symptoms of exercise-induced muscle 
damage has been thoroughly investigated over the past 25 years.  The chief role of NSAIDs is to 
provide analgesia and exert its anti-inflammatory properties.  However, acute inflammation 
initiates repair in muscle tissue, which is necessary for recovery after exercise-induced muscle 
injury (Kumar, Abbas, Fausto, & Mitchell, 2007).  Also, it is difficult to distinguish the analgesic 
effects of NSAIDs from the anti-inflammatory effects when evaluating strength and soreness 
after exercise-induced muscle injury.  Therefore, the precise role of NSAIDs in regards to muscle 
injury has been studied and many different markers of muscle damage, inflammation, and 
muscle recovery have been measured and evaluated.   
NSAIDs are commonly used after muscle injury for their ability to suppress the signs and 
symptoms of inflammation.  The anti-inflammatory activity of NSAIDs is mediated chiefly 
through the inhibition of cyclooxygenase (COX), which converts arachidonic acid to 
prostaglandins (Furst & Ulrich, 2007).  Prostaglandins work by promoting inflammation and 
pain, which are obvious indications of muscle damage.  Rodemann and Goldberg, using 
indomethacin, determined that muscles can synthesize prostaglandins and this synthesis can be 
inhibited by NSAIDs.  This study confirmed that arachidonic acid causes production of 
prostaglandins, which leads to protein degradation, and indomethacin inhibited this degradation 
by inhibiting prostaglandin production (Rodemann & Goldberg, 1982).  This study was in 
agreement with Trappe et al. who found that ibuprofen suppresses the normal increase in 
prostaglandin-F2α (PGF2α ) after resistance exercise, which may substantially influence the 
anabolic actions of this type of exercise (Trappe, Fluckey, White, Lambert, & Evans, 2001).   4
Therefore, NSAID inhibition of COX leads to the inhibition of prostaglandins, which in turn 
relieves the pain and inflammation of a muscle injury.   
There are two isoforms of COX:  COX-1 is constitutively expressed and COX-2 is an 
immediate early response to gene products in inflammatory and immune cells (Smyth & 
Fitzgerald, 2007).  NSAIDs non-selectively inhibit both COX enzymes, while COX-2 inhibitor 
drugs have been developed and are selective for COX-2.  Some NSAIDs, such as aspirin, 
indomethacin, and piroxicam, have proven to be more effective in inhibiting COX-1, while 
ibuprofen and meclofenamate inhibit COX-1 and COX-2 equally (Furst & Ulrich, 2007). 
The production of COX-2, but not COX-1, is essential for early muscle regeneration after 
injury (Bondesen, Mills, Kegley, & Pavlath, 2004).  Bondesen et al. found that after a traumatic 
injury to the tibialis anterior muscle in mice, COX-2 was elevated eight-fold in comparison with 
the serum levels of COX-1, which remained constant with pre-injury levels.  The animals in this 
study were chronically treated with either a COX-1 or COX-2 inhibitor.  During the first seven 
days after injury, the number of regenerating muscle fibers was indifferent in comparison with 
the control in animals chronically treated with a COX-1 inhibitor. However, in animals treated 
with a COX-2 inhibitor, myofiber regeneration was attenuated for the first week following 
injury.  When treated seven days after the tibialis anterior injury with a COX-2 inhibitor, there 
was no change in the recovery of the muscle.  This study indicates that the presence of COX-2 is 
most critical immediately post-injury and validates its role in early muscle regeneration.   
While all NSAIDs operate through inhibition of cyclooxygenase, their differences lie 
primarily in their structure (Imboden, et al., 2007).  This difference in structure contributes to 
varied half-lives within this class of drugs.  Some drugs, such as ibuprofen, have a half-life of 
only two hours, while drugs like nabumetone possess a half-life of  24 hours (Furst & Ulrich,   5
2007).  In the studies that are examining the effect of NSAIDs on muscle recovery, different 
drugs are used, but all are used at anti-inflammatory doses and are dosed accordingly with their 
half-lives.    6
Inflammation 
The inflammatory response is necessary for healing to be initiated and prostaglandins 
play a large role in the inflammatory process (Magee, Zachazewski, & Quillen, 2007).   
Prostaglandins exert effects at the location of muscle damage, including mediation of 
vasodilation and causing an increase in vascular permeability, pain, and fever (Magee, et al., 
2007).  Therefore, with NSAID inhibition of prostaglandin production, the inflammatory process 
is temporarily blunted and cannot mediate tissue repair.   
  The inflammatory process involves many other chemotactic factors in addition to 
prostaglandins.  These include leukocytes, cytokines, oxidants, macrophages, and neutrophils 
(Kumar, et al., 2007).  Macrophages are central to the healing process because they produce 
substances that modulate the inflammatory response.  Macrophages also play a role in satellite 
cell proliferation, which contributes to muscle regeneration (Cantini, et al., 1994).  In early 
inflammation, neutrophils, macrophages, and other leukocytes clean the wound site by 
phagocytosis, debriding the injured area of necrotic tissue, debris, and foreign material within 24 
hours. These mediators then continue to act for the next two to five days (Magee, et al., 2007).   
Macrophages have been considered in clinical trials studying the effect of NSAIDs after 
exercised-induced muscle injury to see if they, like prostaglandins, are affected by NSAID use.  
Cheung and Tidball determined that administration of ibuprofen prior to muscle loading 
increased the concentration of ED2+ macrophages, which have been associated with muscle 
regeneration and repair (Cheung & Tidball, 2003).  The same year, Peterson et al. found that 
macrophage concentrations were significantly elevated after exercise in individuals who 
consumed ibuprofen, acetaminophen, or placebo.  However, the macrophage levels were not 
significantly different between groups, indicating the influx of macrophages occurs after exercise   7
regardless of NSAID use (Peterson, et al., 2003).  The increased macrophage levels in these two 
studies may indicate that inflammation due to exercise-induced muscle damage is not hindered 
by NSAID use.  However, macrophages are not specific to muscle injury because they are 
mediators of all types of inflammation.  Therefore, the presence of macrophages is only one 
component in measuring the response of injured muscle tissue to NSAIDs.  
   8
Exercise-induced muscle injury 
Exercise-induced muscle injury damages stress susceptible muscle fibers and leads to an 
increase in serum muscle enzymes and the development of muscle soreness (Clarkson & 
Tremblay, 1988).  The muscle enzyme released into the serum after exercise-induced muscle 
injury is creatine kinase, a marker of muscle damage.  Creatine kinase is elevated immediately 
following eccentric-contraction induced injury and is still elevated approximately 48 hours after 
injury (Armstrong, Ogilvie, & Schwane, 1983; Malm, et al., 2004).  However, the rise in creatine 
kinase after exercise-induced muscle injury is only significant after the first bout of exercise.  
Muscle rapidly adapts to exercise and less damage is inflicted to the muscle after a subsequent 
bout of the same type of exercise, so there is not a significant rise in creatine kinase (Hirose, et 
al., 2004; Stupka, Tarnopolsky, Yardley, & Phillips, 2001). 
Studies have been inconsistent in showing whether NSAIDs affect creatine kinase levels 
after muscle injury.  It has been demonstrated that anti-inflammatory doses of ibuprofen 
significantly reduced creatine kinase activity compared to placebo when ingested before and 
after exercise (Pizza, Cavender, Stockard, Baylies, & Beighle, 1999).  However, Lecomte et al. 
found that plasma creatine kinase levels were elevated for both naproxen sodium and placebo 
groups in recreationally active males following eccentric exercise. There was not a significant 
difference in the creatine kinase elevations between the NSAID-treated and placebo groups 
(Lecomte, Lacroix, & Montgomery, 1998).  This latter result was reproduced in a 160km run 
with endurance-trained ultramarathoners (Nieman, et al., 2006).  However, ultramarathoners are 
likely to have an attenuated rise in creatine kinase because their muscles have adapted to 
repetitive exercise.  Since these studies utilized subjects who are likely to have different levels of   9
muscle injury after exercise, it is difficult to make a conclusion regarding the role of NSAIDs on 
creatine kinase after exercise-induced muscle injury. 
Exercise-induced muscle injury may also be affected by the timing of NSAID use.  The 
Pizza et al. study administered the NSAID prophylactically and post-exercise while the Lecomte 
et al. study only dispensed the NSAID after exercise.  The study that administered the NSAID 
both before and after exercise resulted in decreased creatine kinase levels, while the study with 
only post-exercise NSAID use did not have lower levels of creatine kinase.   The Nieman et al. 
study administered the NSAID ibuprofen prophylactically, during exercise, and post-race, but the 
individuals who used ibuprofen were habitual users, which may have affected results.  This 
breakdown of research outcomes mildly supports the theory that prophylactic NSAID use 
reduces the amount and possibly even the occurrence of exercise-induced muscle injury and 
inflammation.   
   10
Delayed-onset muscle soreness 
Exercise-induced muscle injury frequently leads to muscular discomfort known as 
delayed-onset muscle soreness (DOMS).  Temporary soreness may persist for several hours 
immediately post-exercise, whereas the residual DOMS appears 24 to 48 hours after 
unaccustomed or strenuous exercise and is characterized by perceived soreness and muscle 
weakness (McArdle, et al., 2001).  DOMS can be attributed to a number of factors: minute tears 
in muscle tissue, muscle spasms, overstretching, tearing of the muscle’s connective tissue 
harness, acute inflammation, or any combination of these factors (McArdle, et al., 2001). 
Physiologically, DOMS can be objectively measured by an increase in serum creatine kinase, 
influx of inflammatory mediators, and a rise in lactate dehydrogenase (LDH) (Kumar, et al., 
2007).  DOMS is also relevant clinically because it is a subjective measure of the effectiveness 
of NSAIDs.  
Delayed-onset muscle soreness is frequently treated with the use of NSAIDs.  It has 
commonly been concluded that NSAIDs significantly reduce perceived muscle soreness at some 
point during recovery after muscle injury (Baldwin, Stevenson, & Dudley, 2001; Dudley, et al., 
1997; Lecomte, et al., 1998; O'Grady, et al., 2000; Sayers, Knight, Clarkson, Van Wegen, & 
Kamen, 2001; Tokmakidis, Kokkinidis, Smilios, & Douda, 2003).  Several studies have found no 
change in perception of DOMS with NSAID use (Bourgeois, MacDougall, MacDonald, & 
Tarnopolsky, 1999; McAnulty, et al., 2007; Nieman, et al., 2006; Pizza, et al., 1999).  However, 
the assessment by McAnulty et al. did not control NSAID dosage during exercise, which the 
study acknowledges and notes may be a cause for its results.    
Timing of drug administration is crucial to the relief of soreness (Hasson, et al., 1993).  
Hasson et al. found that muscle soreness perception was significantly less for at least the first   11
two days after injury when ibuprofen was ingested four hours before exercise and again on two 
occasions after the injury.  When ibuprofen was not given until 24 hours after the injury, the 
subjects did not have a significant reduction in soreness until 48 hours after exercise.  In other 
studies, as long as an NSAID was given within 24 hours after the injury, there was reduction in 
DOMS at some point over the next week (Baldwin, et al., 2001; Lecomte, et al., 1998; Sayers, et 
al., 2001).  There is no evidence that treating DOMS with an NSAID causes an increase in 
perceived muscle soreness.   
   12
Satellite Cells 
The process of injury and repair in muscle after exercise-induced muscle injury also 
involves the activation of satellite cells.  Satellite cells are necessary for myofiber regeneration, 
which usually begins three to six days post injury and peaks around seven to fourteen days 
(Magee, et al., 2007).  These normally quiescent myoblasts will proliferate and differentiate to 
function in regenerative cellular growth, possible adaptations to exercise training, and recovery 
from injury (McArdle, et al., 2001).    
The presence of satellite cells after muscle injury is an indication that an inflammatory 
response is present.  As a mediator of inflammation, macrophages contribute to this rise in 
satellite cell number.  While satellite cells will proliferate mildly in a normal muscle 
environment, they significantly increase in number when macrophages are present (Cantini, et 
al., 1994). 
Satellite cells flourish both after muscle injury and in response to repetitive exercise 
training (Appell, Forsberg, & Hollmann, 1988).  The number of satellite cells begins to increase 
within 24 hours after a single bout of eccentric contractions in both young and older subjects 
(Dreyer, Blanco, Sattler, Schroeder, & Wiswell, 2006).  The increase in cell number is more 
dramatic in younger individuals because they have increased muscle mass in comparison with 
older individuals.  Regardless of the age of the individual, satellite cells increase in response to 
muscle injury and exercise.   
With endurance training, satellite cells quickly begin to adapt to the constant stimulation.  
In a study of older men that trained for four times a week for fourteen weeks on a bike, basal 
levels of satellite cell number in muscle significantly increased by the end of the training period 
(Charifi, Kadi, Feasson, & Denis, 2003).  This study also concluded that the increase in satellite   13
cell number can be attributed to an increase in skeletal muscle function in older men.  The 
increase in satellite cell number also contributed to a significant amount of skeletal muscle 
hypertrophy in the participants.   
It has been proven that satellite cells flourish after exercise.  However, satellite cells are 
significantly decreased after exercise with the use of naproxen (an NSAID) and a COX-2 
inhibitor (Mendias, Tatsumi, & Allen, 2004).  The satellite cell response has also been found to 
be significantly attenuated when indomethacin was ingested prior to endurance exercise 
(Mackey, et al., 2007).  Since satellite cells are required for muscle repair, the lack of a rise after 
injury hinders the regeneration of myofibers.  Although it is expected, this outcome is not 
consistently reproduced.  Results from another study indicated no significant difference between 
treated and control animals in satellite cell proliferation after naproxen sodium treatment 
(Thorsson, Rantanen, Hurme, & Kalimo, 1998).  The latter study administered naproxen 
prophylactically and post-injury, while the Mackey et al. only dosed the NSAID prophylactically 
and Mendias et al. only post-injury.  These results are conflicting and lead to the conclusion that 
satellite cells cannot be the only objective measured after exercise, other markers of muscle 
injury must also be considered. 
   14
Support of NSAID use 
Many studies have shown support of NSAID use for the treatment of exercise-induced 
muscle injury.  These studies administered NSAIDs after the eccentric exercise regimen and 
many times prophylactically as well.  The results from these evaluations failed to find that 
NSAIDs interfered with muscle regeneration and strength gain after eccentric contraction-
induced muscle injury.  Instead, the studies discussed found that NSAID use pre-, during, or 
post-exercise was beneficial to the injured muscle in one or more ways: inflammation was 
lessened, serum creatine kinase elevations were blunted, DOMS reduced, and strength was either 
gained or decreased less compared to placebo.  Clinically, these studies advocate NSAID use 
primarily for its role in decreasing muscle soreness after exercise-induced muscle injury.   
According to a study performed by O’Grady et al., there is strong evidence to support 
NSAID use.  In this study, the experimental group received diclofenac sodium for two weeks 
before and two weeks after strenuous unaccustomed exercise and had resuloution of DOMS after 
only four days (O'Grady, et al., 2000).  This is in stark contrast to the placebo group, which had 
significant perceived soreness for seven days.  Creatine kinase levels were significantly reduced 
in the diclofenac sodium group, relative to placebo, at two out of three measurements taken in 
the two weeks following exercise.  The other measurement taken, which was done two days after 
exercise, showed no difference in creatine kinase levels between the placebo and diclofenac 
sodium group.  Finally, O’Grady et al. found histological evidence of necrotic myofibers and 
inflammation in the muscle of the placebo group after exercise, while neither of these indicators 
of muscle damage was found in the myofibers of the NSAID-treated group.  In summary, this 
study reveals that administration of an NSAID before and after exercise-induced muscle injury   15
has a protective effect on the muscle and reduces DOMS and serum creatine kinase relative to 
placebo.   
Another study found similar histological results when an NSAID was ingested prior to 
exercise-induced muscle injury.  In the experimental group treated with ibuprofen beginning 
eight hours prior to muscle injury, there was a significantly lower amount of necrotic muscle 
fibers compared to the control group and to the group that received ibuprofen beginning after 
injury (Cheung & Tidball, 2003).   Administration of ibuprofen beginning eight hours before 
injury also caused a significant increase in ED2+ macrophages, which are associated with muscle 
regeneration.  It is speculated that this increase in ED2+ macrophages may have worked in 
combination with the NSAID to decrease the number of necrotic muscle fibers in the injured 
tissue (Cheung & Tidball, 2003).     
In a randomized, controlled trial using naproxen sodium after muscle injury, there was a 
positive correlation between NSAID use and DOMS and strength recovery (Lecomte, et al., 
1998).  When muscle soreness peaked three days after exercise, the NSAID group had 
significantly lower perceived soreness than the placebo group.  Quadriceps peak torque after 
exercise at 60°/s, but not at 180°/s or 300°/s, was significantly higher in the NSAID-treated 
group relative to placebo, indicating the possibility of a slight benefit in performance with 
NSAID use.  There was not a significant difference in creatine kinase levels between groups 
during any of the four measurements taken.  It is important to consider that the NSAID was not 
ingested until 24 hours after exercise and this may or may not have had an effect on the 
measured results.  Also, while it is significant that torque increased in the NSAID users at 60°/s, 
since it did not increase at 180°/s or 300°/s it must be contemplated that the increase at 60°/s was 
purely due to the analgesic effects of the NSAID.  It is known that analgesic benefits appear soon   16
after ingestion, but anti-inflammatory levels of NSAIDs in the blood typically aren’t achieved 
until several days after ingesting the first dose (Pizza, et al., 1999).  Therefore, the point when 
the analgesic effects of an NSAID overlap with its anti-inflammatory effects is difficult to 
distinguish, presenting a limitation in this study. 
Both prophylactic and therapeutic administration of ibuprofen can be beneficial after 
eccentric contraction-induced muscle injury, but prophylactic use produces earlier recovery 
(Hasson, et al., 1993).  In an experiment by Hasson et al., the group of subjects receiving 
prophylactic ibuprofen ingested their first dose just four hours prior to exercise and the 
therapeutic group of subjects had their first dose 24 hours after exercise.  Twenty-four hours after 
the exercise bout, the prophylactic group had significantly less decline from baseline in isometric 
force production by the injured muscle.  There was also decreased muscle soreness perception 
compared to the therapeutic, placebo, or control groups, indicating clinical significance for 
NSAID use prior to exercise.  Forty-eight hours after exercise, the prophylactic and therapeutic 
groups had significantly less decrease in force production and lower muscle soreness perception, 
relative to the placebo and control groups.  A limitation to this study is that muscle soreness, 
torque, and damage were only measured for 48 hours after the eccentric contraction-induced 
muscle injury.  It would be advantageous to conduct this study for a longer period of time to 
learn the effect of long-term NSAID use on muscle after injury.  Also, once again it must be 
considered that the decrease in muscle soreness and the less significant decline in force 
production among the NSAID users could have been due to analgesic effects of the drug.  
However, for the participants, the analgesic effects are impossible to differentiate from the anti-
inflammatory properties of the drug.   17
While most evaluations of eccentric contraction-induced injury analyzed damage to leg 
muscles, a study by Sayers et al. evaluated injury of the elbow flexors instead.  The protocol 
included a relatively large number of participants, with 48 integrated into the final results, further 
validating the outcome.  Ketoprofen was administered in either 100mg or 25mg doses.  When 
ingested 36 hours after injury, ketoprofen-100mg and ketoprofen-25mg attenuated muscle 
soreness 10% and 19%, respectively, while a placebo decreased soreness only 1%.  It is not 
especially significant that the larger dose of ketoprofen decreased soreness less because soreness 
is a subjective measure.  A similar result was found when maximal isometric force (MIF) of the 
injured muscle was measured after exercise: ketoprofen-100mg increased MIF 16%, ketoprofen-
25mg increased MIF 9%, and placebo decreased MIF 9%.  This increase in MIF after ketoprofen 
administration represents strength gain, presumably attributable to the NSAID.  However, since 
different doses were used, whether it was the anti-inflammatory or analgesic effects of the 
NSAID that produced these results remains undetermined and as mentioned before, difficult to 
distinguish.  This is only a small limitation to the study.  The fact that this study measured upper 
extremity muscles instead of the more commonly measured lower extremity muscles may also 
contribute to some variation in results.  Regardless, the significant outcomes lead researchers to 
conclude that ketoprofen administered after injury decreases muscle soreness and improves force 
recovery (Sayers, et al., 2001).   
The preceding results were in agreement with another study that found naproxen sodium 
to reduce perceived muscle soreness and improve recovery (Dudley, et al., 1997).  Four days 
post-exercise, the naproxen-treated group in this study had significantly reduced soreness and 
less of a decline in their one-repetition maximum contraction, suggesting enhanced muscle 
regeneration with naproxen sodium.  Also similar to the trial above, the NSAID in this study was   18
not administered until after the exercise-induced injury had occurred.   However, this study 
employed a testing field of only eight subjects, which is relatively small and somewhat lessens 
the validity of the results.   
Positive effects of NSAIDs as treatment for muscle injury can also be found in the older 
population.  A study by Baldwin et al. (2001) looked at older men and women and determined 
the effect of naproxen sodium administration after muscle injury for this unique population.  
Even though the subject age was atypical, the results of this study are very much analogous to 
what aforementioned researchers ascertained.  After only three days, older participants who 
ingested naproxen sodium after exercise had significantly decreased soreness and less of a 
decline from their baseline isometric strength measurement.  Once again, naproxen sodium use 
attenuated injury and loss of muscle function and therefore resulted in less strength loss and 
reduced soreness during recovery. 
A study at the University of Thrace found that ibuprofen ingestion after an eccentric 
exercise regimen causes decreased soreness perception and reduced creatine kinase activity after 
48 hours (Tokmakidis, et al., 2003).  This study also found that maximal strength, vertical jump 
performance, and knee range of motion (ROM) decreased significantly after exercise and there 
was not a significant difference between the ibuprofen and placebo groups.  This evidence 
reveals ibuprofen is beneficial to decrease soreness and muscle damage, but does not assist in 
restoring muscle function after injury.  The decrease in soreness and muscle damage is most 
advantageous clinically, when the damaged muscle group needs to be utilized soon after the 
injury.   
While the studies formerly presented found evidence in support of NSAID use, some 
studies discerned only a slight advantage in their utilization.  Donnelly et al. detected no   19
difference between diclofenac sodium and placebo groups except that muscle soreness was 
reduced at several points with the use of diclofenac sodium (Donnelly, McCormick, Maughan, 
Whiting, & Clarkson, 1988).  At the very least, the reduction in soreness is clinically significant 
for prescription NSAID use. A study in 1999 identified the only advantage to naproxen sodium 
use was an earlier return to baseline for maximum volumetric contraction of the injured muscle 
(Bourgeois, et al., 1999).  This suggests that NSAIDs hasten muscle regeneration. Participants in 
both of the aforementioned studies received their first dose of the NSAID prior to exercise, 
promoting prophylactic NSAID use for both its clinical and histological advantages.    
As mentioned earlier, another common measurement of the influence of NSAIDs on 
muscle recovery is the number of satellite cells present in the injured muscle.  However, none of 
the studies with results that support NSAID use measured satellite cells.  Interestingly, all of the 
studies that did measure satellite cells found either no consequence to NSAID use or discovered 
that NSAID exploitation hinders muscle recovery (Mackey, et al., 2007; Mendias, et al., 2004; 
Rahusen, Weinhold, & Almekinders, 2004; Thorsson, et al., 1998). 
The studies listed above display evidence to support NSAID use for the treatment of 
exercise-induced muscle damage.  When taken prophylactically, NSAIDs were found to decrease 
serum creatine kinase, decrease perceived muscle soreness and hasten its resolution, decrease 
necrosis, increase ED2+ macrophages to help with reparation of the muscle, and cause less of a 
decline in force production by the muscle after exercise-induced muscle injury (Bourgeois, et al., 
1999; Cheung & Tidball, 2003; Donnelly, et al., 1988; Hasson, et al., 1993; O'Grady, et al., 
2000).  When the NSAID was ingested after eccentric contraction-induced muscle injury, 
decreased soreness, quicker resolution of soreness, and less of a decline in muscle strength 
relative to placebo were all reported (Baldwin, et al., 2001; Dudley, et al., 1997; Lecomte, et al.,   20
1998; Sayers, et al., 2001; Tokmakidis, et al., 2003).   Whether the NSAID was used 
prophylactically or therapeutically, the results indicate that there is clear clinical advantage with 
its use.  However, of the studies that support therapeutic use, one had only eight test subjects and 
another tested the elbow flexors instead of the more common quadriceps.  These are small 
limitations, since so many other studies were able to reproduce their results.      
In evaluation of the studies that support NSAID use, there is substantial evidence 
supporting the clinical advantages obtained with NSAIDs.  One of the most compelling 
conclusions of these supporting studies is that the use of NSAIDs causes less of a decline in 
muscle strength after injury and permits improved performance.  However, it must be considered 
that the subjects in these studies were able to perform post-exercise muscular contractions closer 
to their baseline strength due to the analgesic effects of the NSAID (Mishra, et al., 1995).  The 
analgesic benefits appear soon after ingestion, but anti-inflammatory levels of NSAIDs in the 
blood typically aren’t achieved until several days after the initial dose (Pizza, et al., 1999).  If 
this is the case, then it is possible that the subjects in the placebo-treated groups did not contract 
their muscles to their maximum ability due to discomfort or pain.  This result is plausible since 
DOMS was lessened and resolved sooner with NSAID treatment (Baldwin, et al., 2001; Dudley, 
et al., 1997; Hasson, et al., 1993; Lecomte, et al., 1998; Sayers, et al., 2001; Tokmakidis, et al., 
2003).  However, analgesic and anti-inflammatory effects of NSAIDs are nearly impossible to 
differentiate for both the researcher and the subject with the exercise-induced muscle injury.  
Therefore, the analgesic effects of NSAIDs are predominantly only significant for the 
measurement of DOMS.   
Results that are likely indisputable include the lack of histological evidence of muscle 
necrosis and less of a rise in serum creatine kinase in NSAID-treated muscles compared to   21
control or placebo-treated muscles.  A previously discussed study performed by O’Grady et al. 
(2000) boasted both of these results.  However, this study began administering diclofenac 
sodium a full two weeks prior to exercise.  It is speculated that the duration of treatment may 
have had a protective effect on the muscle following eccentric exercise (Pizza, et al., 1999).  So 
far, the effects of prolonged NSAID administration on exercise-induced muscle damage have not 
been reported (O'Grady, et al., 2000).  Another study found a similar lack of muscle necrosis, but 
only in subjects treated with NSAIDs prophylactically and not those who began treatment at the 
time of injury (Cheung & Tidball, 2003).  In this study, the prophylactic dose was given only 
eight hours prior to injury, so protective effects are less of a concern.   
The decrease in perceived soreness and DOMS and its quick resolution compared to 
placebo is also fairly indisputable.  NSAIDs inhibit prostaglandins, which promote pain, so it is 
logical that DOMS is hindered with their use.  Some studies to be discussed later failed to uphold 
this statement (Bourgeois, et al., 1999; Donnelly, Maughan, & Whiting, 1990; Nieman, et al., 
2005).  However, these studies had limitations in their design which will be discussed in the 
following chapters. 
In summary, significant evidence exists to support the clinical use of NSAIDs as 
treatment for exercise-induced muscle injury.  There are some limitations, such as the unknown 
extent of the analgesic benefits of NSAIDs, that put into question the supposed strength gains 
produced by the drug (Mishra, et al., 1995).  The possible effects of long-term administration of 
NSAIDs are also uncertain, simply because they have been explored in only one study (Pizza, et 
al., 1999).  There aren’t any studies measuring satellite cells that uphold the use of NSAIDs as 
advantageous, but there also are not any studies which denounce NSAID use due to satellite cell 
response.  Timing of NSAID administration is also a factor and seems to play a crucial role in   22
recovery (Hasson, et al., 1993).  From the studies discussed above, prophylactic NSAID use has 
produced more clinically significant results than therapeutic use, but therapeutic use still reduces 
muscle soreness and causes less of a decline from baseline strength.  In summary, the limitations 
to the discussed studies are few and significant evidence has been produced to support the 
clinical use of NSAIDs both before and after exercise-induced muscle injury.     23
Conflict with NSAID use for the Treatment of Muscle Injury 
There have been numerous studies that suggest NSAIDs delay muscle recovery and 
hinder strength gain.  Almekinders et al. (1986) investigated the healing process of muscle 
strains and the effect of piroxicam in the eleven days following injury.  The control group in this 
study displayed proof of muscle regeneration after only four days, whereas the piroxicam-treated 
group showed only slight restoration at this point.  The control group also had significantly less 
aberration from baseline muscle strength in the first few days post-injury.  It was determined that 
muscle strains continue to weaken in the early post-injury period and that piroxicam 
administered post-injury delayed the inflammatory reaction and muscle regeneration. 
NSAIDs have been shown to blunt protein metabolism in animals (Rodemann & 
Goldberg, 1982).  In 2002, Trappe et al. performed a verifiable study on the effect of ibuprofen 
on human post-exercise muscle protein synthesis (Trappe, et al., 2002).  Based on microscopic 
analysis of the vastus lateralis muscle, it was determined that the muscle protein fractional 
synthesis rate (FSR) was unchanged after exercise in the ibuprofen-treated group.  This was in 
discord with the control group that had increased FSR after exercise, suggesting muscle protein 
synthesis and eventually muscle growth.  This study also found no significant differences in 
creatine kinase elevations and perceived muscle soreness between the NSAID-treated and 
control groups.  This evidence concludes that NSAID use beginning at the time of injury 
attenuates muscle protein synthesis and possibly inhibits the normal anabolic response to 
eccentric contraction exercise training. 
At 2004 study determined that COX-2 is essential for early muscle repair after injury 
(Bondesen, et al., 2004).  In 2005, Soltow et al. further investigated this conclusion, but 
expanded their research by incorporating NSAIDs into their study and by also analyzing strength   24
gain. Fourteen days after overloading the plantaris muscle, ibuprofen-treated rats exhibited 
muscles that were only 29% larger than baseline muscle.  In contrast, control rats muscles were 
60% larger than the normal, untreated muscle.  For L-NAME, a COX-2 inhibitor, muscles 14 
days after injury were 42% larger, but the control muscles were 87% larger than the baseline 
muscle.  These results confirmed that COX is necessary for a muscle to reach its full extent of 
hypertrophy after exercise and that both ibuprofen and L-NAME blunted skeletal muscle 
hypertrophy when compared to control animals (Soltow, et al., 2006).   
Time-dependent effects of NSAIDs also play a crucial role in strength gain.  In 1995, 
unprecedented research was conducted to examine the time-dependent effects of NSAIDs on 
eccentric contraction-induced injury by following the subjects for 28 days post-injury (Mishra, et 
al., 1995).  It was concluded that flurbiprofen administered after exercise resulted in short-term 
improvement of muscle strength 3 and 7 days post-injury, but there was a subsequent deficit in 
muscle strength 28 days after injury.  The short-term improvement in this study was represented 
by lower creatine kinase values and faster recovery of torque generation in the NSAID-treated 
subjects at 3 and 7 days after exercise. At 28 days after injury, there were no significant 
differences between treated and control animals for creatine levels..  It is proposed that by 
suppressing the initial inflammatory reaction, the drug permits improved performance early post-
injury.  However, suppressing the inflammatory process may have also curbed the stimulus 
needed for cellular remodeling and strength gain.  This result is compounded by evidence from 
another study.: inflammation is necessary for resultant skeletal muscle hypertrophy after 
exercise-induced muscle injury (Soltow, et al., 2006). 
Research in 2004 found that COX-2 expression by satellite cells is blunted after exposure 
to NSAIDs following exercise-induced muscle injury (Mendias, et al., 2004).  In this study,   25
when injured muscle cells were exposed to either a COX-2 inhibitor or naproxen sodium, 
satellite cells failed to proliferate, differentiate, and fuse.  There was no attenuation in satellite 
cell production for the muscles that were injured, but not exposed to an NSAID.  Since satellite 
cells are needed for muscles to regenerate, NSAID inhibition of satellite cells can lead to a delay 
in muscle recovery and eventual inhibition of muscle hypertrophy. 
As discussed earlier, endurance training elicits an increase in satellite cell number 
(Charifi, et al., 2003).  In a study by Mackey et al. (2007), endurance trained athletes ingested 
either indomethacin or a placebo beginning four days prior to a 36km run.  After the run, 
biopsies were taken on three occasions and were analyzed for satellite cells.  The NSAID-users 
had no change in satellite cell number compared to their baseline measures, while the placebo 
group had a 27% increase in satellite cell number as early as eight days post-exercise.  These 
results suggest that the ingestion of NSAIDs prior to eccentric contraction-induced muscle injury 
inhibits satellite cell proliferation in endurance trained athletes. 
A couple of studies found only one difference each between NSAID-treated and control 
subjects (Donnelly, et al., 1990; McAnulty, et al., 2007).  McAnulty et al. found no significant 
differences between groups for any of the markers of muscle injury or oxidative stress, except for 
an increase in DOMS one day after injury for NSAID-users.  However, this study did not control 
dosage or the type of NSAID used, so this odd increase in DOMS with NSAID use should likely 
be considered an exception to the rule.  Donnelly et al. found that DOMS ratings and maximum 
contraction following exercise did not differ between NSAID-treated and untreated subjects 
following a downhill run.  However, it was found that creatine kinase elevations and urea 
concentration were both significantly greater in ibuprofen-users compared to non-users.  The   26
authors of this study were surprised by the latter results and attribute them to the effects of 
ibuprofen on plasma volume and protein content. 
The evidence presented in this chapter strongly advocates against NSAID use for the 
treatment of exercise-induced muscle injury.  Whether taken prophylactically or after exercise, 
NSAIDs were found to inhibit satellite cell proliferation and more importantly to attenuate long-
term strength gains and impede the anabolic action normally produced by eccentric exercise 
(Almekinders & Gilbert, 1986; Mackey, et al., 2007; McAnulty, et al., 2007; Mendias, et al., 
2004; Mishra, et al., 1995; Soltow, et al., 2006; Trappe, et al., 2002).  The goal of eccentric 
exercise is typically to increase muscle mass, and these results have indicated that NSAIDs will 
disrupt this process for up to 28 days, the longest time period studied.  Therefore, NSAIDs are 
erasing some of the benefits normally associated with eccentric exercise, in exchange for slight 
reduction in DOMS and a possible decrease in total muscle damage.  However, the decrease in 
soreness and muscle damage is significant clinically and remains one of the reasons that NSAIDs 
are so commonly prescribed for muscle strains and sprains and other muscle injuries.  After a 
muscle injury, only a small percentage of NSAID users are concerned with satellite cell 
inhibition and delay of strength gain, so the information presented in this chapter is of little 
consequence to the majority of NSAID users and their prescribing clinician.   
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NSAIDs Role in Muscle Recovery is not Significant 
Additional studies have essentially found no consequence in using NSAIDs for the 
treatment of eccentric contraction-induced muscle injury.  In a study by Pizza et al. (1999), 
ibuprofen was taken for five days prior to exercise and continued for ten days after.  Creatine 
kinase levels were reduced three days post-injury for the ibuprofen group relative to the placebo 
group.  However, there was no difference between groups for neutrophil count, isometric 
strength, soreness, and arm angles.  Therefore, post-exercise strength and inflammation were 
apparently unaffected by NSAID use.   
Naproxen sodium was formerly reported to have both positive and negative effects on 
muscle post-injury (Baldwin, et al., 2001; Dudley, et al., 1997; Mendias, et al., 2004)  However, 
it has also been found to have no significant effect whatsoever (Bourgeois, et al., 1999; 
Thorsson, et al., 1998).   Bourgeois et al. examined the effects of naproxen sodium on delayed-
onset muscle soreness, creatine kinase level, and inflammatory cell number and found no 
significant difference between the treated and control groups for any of these markers.  In this 
study, however, moderately trained subjects were used and trained subjects are likely to have an 
attenuated creatine kinase and inflammatory cell release after repeated exercise (Stupka, et al., 
2001).   
A couple of evaluations found no difference between treated and control animals in 
satellite cell proliferation after NSAID treatment (Rahusen, et al., 2004; Thorsson, et al., 1998). 
However, the mechanism of injury in both of these studies was a contusion injury and not due to 
eccentric contractions.  The physiological difference in this type of injury may have affected 
results, so it is not clear that NSAIDs truly have a negligible effect on satellite cell number.     28
A study of ultra-marathoners found that creatine phosphokinase, cytokines and delayed-
onset muscle soreness were all elevated after a 160km race, but the elevations were not 
significantly different between NSAID users and non-users (Nieman, et al., 2005).  While this 
study had a large number of subjects, the groups of NSAID users and non-users were 
disproportionate, with 72% reportedly using an NSAID.  Also, the dosage of the NSAID was not 
controlled, so it is not known if subjects were taking doses that may have had more or less of an 
impact on the measured markers.  These limitations in the design of the study stimulated the 
authors to revamp it.  The second study performed by Nieman et al. (2006) controlled the dosage 
of the NSAID and approximately 50% of subjects were reported as NSAID users.  This time, 
ibuprofen use resulted in significantly higher levels of cytokines, neutrophils, and leukocytes, 
which are all indicators of inflammation.  There was no significant difference in creatine kinase 
elevations and DOMS between NSAID users and non-users.  These results are somewhat similar 
to the first study and in basically denounce NSAID use due to a lack of evidence of substantial 
benefit with their utilization. 
Whether taken prophylactically or post-exercise, NSAIDs have been shown to have no 
significant role in the creatine kinase response of injured muscles (Bourgeois, et al., 1999; 
Donnelly, et al., 1988; Hasson, et al., 1993; Lecomte, et al., 1998; McAnulty, et al., 2007; 
Nieman, et al., 2006; Trappe, et al., 2002).  Since creatine kinase is one of the markers of muscle 
damage, the deficiency of a significant difference in creatine kinase level between NSAID 
treated and untreated subjects in so many studies implies that NSAIDs do not play a role in 
protection from muscle damage.  However, creatine kinase in not only significant in muscle 
injury because a rise in creatine kinase may also reflect heart or brain injury.  McAnulty et al. 
found that in addition to creatine kinase, NSAID use did not diminish any oxidative stress   29
markers after exercise. However, this study did not control the dosage of the NSAID, so results 
are limited. 
Macrophages and neutrophils, key inflammatory markers, did not differ in number 
between ibuprofen users and non-users after eccentric contractions of the knee flexors (Peterson, 
et al., 2003).  In this study, ibuprofen was ingested beginning right after exercise.  A large 
drawback in this study is that inflammatory cells were only measured once, 24 hours after 
exercise.  Since the ingestion of ibuprofen was after exercise, it would have taken time for the 
NSAID to reach a steady state concentration in the blood, so results after 24 hours, had they been 
taken, may have been significant.  This lack of long-term measurement limits the outcome 
reported in this study.   
While the evidence presented in this chapter argues that NSAIDs do not play a significant 
role on muscle post-injury, limitations exist within nearly every study.  Whether it was lack of 
control of NSAID dosage, mechanism of injury, length of the study, or the characteristics of the 
subjects, all of the studies except one, by Pizza et al., had an identifiable weakness.  Therefore, 
there is not enough evidence to uphold the supposed outcome that NSAIDs have no effect on 
muscle recovery and strength after eccentric contraction-induced injury.   30
Conclusion 
Although the pharmacology of NSAIDs and the processes of inflammation and of muscle 
recovery after eccentric contraction-induced muscle injury have been established, it has proven 
difficult to confirm their interactions with one another.  Studies have been performed and come 
to a variety of conclusions: NSAIDs improve muscle recovery, NSAIDs hinder muscle recovery, 
and NSAIDs do not have a significant effect on muscle post-injury.  After intense review, 
limitations were found in some of the studies and the recommendation for the use of NSAIDs as 
treatment for exercise-induced muscle injury is primarily based on its clinical benefits.   
  Many of the studies evaluated have outcomes that strongly favor the utilization of 
NSAIDs.  Studies performed by O’Grady et al. (2000) and Cheung & Tidball (2003) both 
administered NSAIDs prophylactically and therapeutically and found evidence of decreased 
necrosis in the muscles of NSAID users post-exercise.   This histological evidence cannot be 
disputed.  However, both of these studies utilized NSAIDs prior to exercise and the protective 
effect of NSAIDs has yet to be researched.  Future research is needed in order to assess the 
benefits and drawbacks of long-term NSAID use because for now, the longest study performed 
measured results for only 28 days post injury (Mishra, et al., 1995).   
Several of the studies that supported NSAID use brought into question the extent of the 
analgesic effect of NSAIDs.  Most studies administered the NSAID post-injury and claimed to 
decrease muscle soreness and cause either less of a decline from baseline strength measurements 
or strength gain with NSAID use (Baldwin, et al., 2001; Dudley, et al., 1997; Hasson, et al., 
1993; Lecomte, et al., 1998; Sayers, et al., 2001; Tokmakidis, et al., 2003).  The decrease in 
perceived soreness is rather indisputable since it results from both the analgesic and anti-
inflammatory effects of NSAID, due to the inhibition of prostaglandins.  The strength benefits,   31
however, are not as clear.  It is possible that the reason NSAID users were able to perform 
superiorly post-injury was simply because less pain was experienced with NSAID use or that the 
pain felt by non-users caused them to perform inferiorly.  The analgesic effects of NSAIDs occur 
quickly after ingestion, but the anti-inflammatory effects take several days to acquire (Pizza, et 
al., 1999).  However, as discussed many times, we cannot distinguish these two effects.  
Regardless of whether it is due to a reduction in pain or inflammation, NSAID users are able to 
perform closer to baseline sooner than non-users after exercise-induced muscle injury (Hasson, 
et al., 1993; Sayers, et al., 2001).   
In addition to reducing muscle soreness and providing protection from muscle damage, 
NSAID use is also supported because of its role in reducing creatine kinase levels, increasing the 
concentration of ED2+ macrophages, and reducing inflammation (Bourgeois, et al., 1999; 
Cheung & Tidball, 2003; Donnelly, et al., 1988; Hasson, et al., 1993; O'Grady, et al., 2000; 
Tokmakidis, et al., 2003).  While these latter measurements are less significant clinically, they 
lead to a reduction in pain and soreness, which are two of the most important clinical complaints 
after exercise-induced muscle injury.  These important factors, along with additional studies that 
indicate NSAIDs enhance recuperation, lead to support of NSAID use for the treatment and 
prevention of exercise-induced muscle injury (Dudley, et al., 1997).    
Of the few studies that found no consequence with NSAID use, there were limitations in 
all but one.  The use of trained subjects, a very short study length, contusion injuries, and no 
monitoring of NSAID dosage were some of the errors found that likely affected results 
(Bourgeois, et al., 1999; Nieman, et al., 2005; Nieman, et al., 2006; Peterson, et al., 2003; 
Rahusen, et al., 2004; Thorsson, et al., 1998).  Also, the results that were produced in these 
studies are fairly small findings in comparison with other studies and varied from one study to   32
another.  One common finding was that creatine kinase levels were frequently unaffected by 
NSAID use (Bourgeois, et al., 1999; Donnelly, et al., 1988; Hasson, et al., 1993; Lecomte, et al., 
1998; McAnulty, et al., 2007; Nieman, et al., 2006; Trappe, et al., 2002).  This indicates that 
NSAIDs did nothing to protect muscles from damage during exercise.  In total, the results of 
these studies are uncertain at best and other than the observation regarding creatine kinase, the 
idea that NSAIDs do not play a significant role in muscle recovery after injury is weakly 
supported. 
Finally, the research that criticizes NSAID use is significant and focuses primarily on the 
delay in muscle regeneration, inhibition of satellite cells, and the blunted skeletal muscle 
hypertrophy associated with NSAIDs.  NSAIDs inhibit COX-2, which is necessary for muscle 
regeneration (Bondesen, et al., 2004).  The studies that condemn NSAID utilization for the 
treatment of exercise-induced muscle damage exhibit this important fact over and over.  These 
studies found evidence that NSAID use blunted protein synthesis, inhibited skeletal muscle 
hypertrophy, attenuated the satellite cell response, and essentially negated the anabolic results 
normally produced after eccentric exercise (Almekinders & Gilbert, 1986; Mackey, et al., 2007; 
Mendias, et al., 2004; Mishra, et al., 1995; Soltow, et al., 2006; Trappe, et al., 2002).  This 
evidence also suggests that inflammation, which is attenuated with NSAID use, is necessary for 
muscle repair and strength gain.  There were few limitations discovered in any of these studies, 
solidifying these conclusions.  It is also important to note that all of these studies, except for that 
by Mackey et al., administered NSAIDs immediately post-injury as opposed to prophylactically. 
While the musculoskeletal disadvantages of NSAID are significant histologically, these 
important findings are most likely to be significant only to athletes, those who frequently 
exercise, and habitual NSAID users.  The adverse effects on muscle growth associated with   33
NSAID use are not likely important factors to most clinicians when prescribing NSAIDs.  They 
are also not imperative facts for the average individual who suffers a muscle injury and simply 
seeks relief from pain and soreness.    
 It can be concluded that NSAID use for the treatment of exercise-induce muscle injury is 
partially detrimental due to the hindrance of skeletal muscle repair and hypertrophy, but that 
clinically these effects are less important.  The inhibition of muscle growth after exercise is 
primarily important for athletes and individuals who are exercising in order to gain strength and 
muscle mass.  It is also important for those who will be using NSAIDs habitually, since we do 
not know the long-term effect of NSAIDs on muscle.  However, most NSAID-users are not 
concerned with these side-effects and continue to use NSAIDs.  Therefore, for an individual 
simply seeking relief from pain and soreness associated with muscle injury and not concerned 
with the inhibition of muscle hypertrophy associated with NSAID use, this class of drugs is 
recommended.  Clinically, NSAIDs continue to be the mainstay of treatment for a variety of 
muscular aches and pains and their role has been supported after this review of the literature.     34
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Methods used    Study groups 





- Rat muscle 
strained by machine 
and then 
immobilized 
- 85 rats 
- Therapeutic  
NSAID
1 use vs. 
control 
 
- Wet weight of 




- Maximum failure 
load 
- Histology showed a 
delay in inflammatory 
reaction and muscle 
regeneration in the 
NSAID group 
- Wet weight ↑ 
significantly less for 
NSAID group vs. control 
- Control group had less 
strength loss and earlier 
regeneration 
Baldwin, et al., 
2001 
- 64 knee extensions 
performed  
- Strength measured 
before exercise, at 
day 3 and day 10 
- 10 men and 5 




NSAID use vs. 
placebo 
 
- Muscle strength 
before and after EIMI
2 
- Muscle soreness 




- Strength declined less 
for NSAID than placebo 
- ↑ soreness after exercise 
with placebo vs. NSAID 
- Placebo users had 
significantly increased 
EIMI and edema on MRI 
on days 3 and 10  
Bourgeois, et al., 
1999 
- Leg press and 
knee extension 
- 8 resistance and 
aerobic trained men 
- Prophylactic 
naproxen sodium 









- No significant 
difference (SD) in 
elevations of CK or 
DOMS between placebo 
vs. NSAID 
- MVC ↓ for both groups 
at 24h and still for 
placebo at 48h – NSAID 




- Rats had 
suspended hindlimb 
for 10 days, 
followed by normal 
loading to induce 
inflammation 








- ED1 and ED2+ 
macrophages 
- Histological 
evaluation of muscle 
- Prophylactic NSAID 
use resulted in ↓ muscle 
necrosis and ↑ 
macrophage (ED2+) 
- No significant ∆ in the 
group that received 
NSAID after muscle 
loading 
Dudley, et al., 
1997 
- 10 sets of 7-10 leg 
extensions at 85% 
of 1RM
7 
- 2 phases (second 
phase with other 
leg) 
- 9 males, not 
resistance trained 
- Therapeutic 
NSAID use vs. 
placebo 
 
- 1 RM 
- DOMS 
- ↑ 1RM at day 4 with 
naproxen sodium 
- ↓ DOMS at day 4 with 
naproxen sodium   41
 
Hasson, et al., 
1993 
- Bench step-ups  
- 20 subjects, males 
and females not 










- CK level 
 
- ↑ CK in prophylactic 
and therapeutic groups at 
24 and 48h with no SD 
- Prophylactic NSAID 
use resulted in ↓ soreness 
and less decline from 
baseline in torque and 
MVC, with therapeutic 
results lagging 24h 
behind 
 
Lecomte, et al., 
1998 
- Eccentric leg 
exercises on days 1, 
3, and 4 – (2 testing 
phases lasting 8d 
and separated by 
1wk) 
- Exercised vs. 
control leg 
- 20 males, not 
resistance trained 
- Therapeutic 
NSAID use vs. 
placebo 
 
- CK level 
- DOMS 
- Quad strength 
- ↑ CK in both groups 
with no SD 
- ↑quad strength for 
NSAID at 60◦/s (no SD 
for 180 and 300◦/s) 
- ↓ DOMS on day 3 with 
NSAID use 
Mackey, et al., 
2007 
- 36km race 
- 14 endurance 
trained athletes 
- Prophylactic 
NSAID use vs. 
placebo 
- NSAID ingested 




8 count  -↓ number of SCs after 
exercise with NSAID use 
- SCs are increased after 
exercise without NSAID 
use 
Mendias, et al., 
2004 




COX-1 inhibitor, or 









- SC proliferation and 
differentiation 
- ↓ in SC proliferation 
with naproxen sodium 
and COX-2 inhibitor 
- Inhibition of COX-1 
and 2 results in ↓ and 
differentiation of SCs 
Mishra, et al., 
1995 
- Rabbit leg has an 
induced eccentric 
injury 







- CK level 
- Flurbiprofen resulted in 
short term improvement 
in maximum contraction 
at 3d and 7d, but deficit 
at 28d 
- ↓ CK in flurbiprofen 
users at 3d and 7d, but 
not at 28d 
Nieman, et al., 
2005 
- 160km run 
- 45 men and 15 
women 
- NSAID use vs. 
control 
- Dosage and type 
of NSAID not 
controlled 
 
- CK level 
- DOMS 
- Cytokine level 
- CK, DOMS, and 
cytokines ↑ after race for 
both groups, but no SD 
between NSAID users 
and control 
   42
 
Nieman, et al., 
2006 




- NSAID use vs. 
control 




- CK level 
- Leukocyte count 
- Neutrophil count 
- LPS
9 (measure of 
endotoxemia) 
- No SD in CK level 
between ibuprofen users 
and control 
- ↑ cytokines, 
neutrophils, leukocytes, 
and LPS levels with 
ibuprofen use 
O’Grady, et al., 
2000 
- 20 minutes of 
step-ups 





use vs. placebo 
- NSAID use 
began 14d prior to 
exercise 
 
- CK level 
- DOMS 
 
- ↓ CK level with 
diclofenac sodium and ↑ 
CK with placebo 4d after 
exercise 
- CK levels SD 14d after 
exercise 
- ↓ DOMS with 
diclofenac sodium use 
Peterson, et al., 
2003 
- Eccentric 
contractions of knee 
extensors 
- 24 untrained males 
- Therapeutic 
ibuprofen use vs. 
therapeutic 
ACET
10 use vs. 
placebo 
 
- Macrophage count 
- Neutrophil count 
- Macrophages 
significantly ↑ in all 
groups 24h after exercise, 
while neutrophils did not 
∆  
- Inflammatory cell 
concentrations were 
unaffected by ibuprofen 
or ACET use 
Pizza, et al., 1999  - 2 bouts of one arm 
exercises done 
3wks apart   
- 10 sedentary 
males 
- Therapeutic 
ibuprofen use vs. 
control 
- NSAID ingested 
for 5d before and 
10d after exercise 
 
- CK levels 
- Neutrophil count 
- DOMS 
- Isometric strength 
- CK levels SD 3d after 
exercise when placebo 
CK levels were ↑ 
- No change in neutrophil 
response, except at 10d 
when significantly ↑ for 
NSAID users 
- No SD in soreness or 
strength between groups 
Rahusen, et al., 
2004 
- Mice given 
contusion injury 
- 96 mice 
- Tx with COX-2 
inhibitor after 
injury vs. COX-2 
inhibitor 24h 
before injury vs. 
ACET after injury 
vs. placebo 
 
- Gait disturbance 
- Wet weight of 
muscle (measure of 
edema) 
- SC count 
- No significant ∆ in SC 
count with NSAID, 
ACET, or placebo 
- Wet weight ↑ for 
placebo only  
- Gait disturbance 
significantly ↑ for 
placebo group 
Sayers, et al., 
2001 
- 50 max eccentric 
contractions of the 
elbow flexors 




ketoprofen vs.  
placebo  
- All ingested 36h 
after exercise 
 
- Max isometric force 
- Muscle soreness 
- EMG
11 
- Ketoprofen ↓ soreness 
and ↑ max isometric 
force recovery compared 
to placebo 
- ↑ EMG for all groups 
after exercise and 
ketoprofen did not reduce 
this at all   43
 
Soltow, et al., 
2006 
- Rat muscle 
overloaded (OL) or 
normal loaded (NL) 
- 16 rats 
- Therapeutic 
ibuprofen vs. L-
NAME (a COX-2 
inhibitor) vs. 
control 
- Muscle protein 
- Macrophage count 
- Neutrophil count 
- Control rats ended up 
with larger muscles → 
Hypertrophy blunted by 
NSAID use 
- Macrophages elevated 
2x in OL vs. NL muscles  
- Neutrophil count didn’t 
∆ 
Thorsson, et al., 
1998 
- Rats hit with 
mallet to induce 
contusion 
- 4 groups of 12-16 
rats each 
- Naproxen 
sodium 6h after 
injury vs. 
naproxen sodium  
3d after injury vs. 
2 control groups 
- SC proliferation 
 
- No difference between 
NSAID and control 
groups in SC count after 
injury 
- Note: injury was a 
contusion injury and was 




- 6 sets of 10 reps of 
leg curls 
- 14 men and 5 
women who were 









- Leg curl max 
strength 
- Vertical jump 
performance 
- ↓ CK at 48h and 
↓DOMS at 24h with 
NSAID use 
- Ibuprofen did not 
accelerate recovery of 
ROM, strength, or jump 
performance 
 
Trappe, et al., 
2002 
- 10-14 sets of 10 
high-intensity 
eccentric exercises 
with knee  
extensors 
- 24 sedentary 
males 
- Therapeutic 
ibuprofen vs.  
therapeutic ACET 
vs. placebo  
- CK level 
- Muscle protein 
fractional synthesis 
rate (FSR) 
- ↑ CK in all groups after 
exercise with no SD 
between groups 
- ↑ FSR only in placebo 
- Ibuprofen and ACET 




 1 – Nonsteroidal anti-inflammatory drug; 
2 
– Exercise-induced muscle injury;  
3 – Magnetic resonance; 
4 – Delayed-onset muscle soreness; 
5 – Creatine kinase; 
6 – Maximum 
volumetric contraction; 
7 – Repetition maximum; 
8 – Satellite cell; 
9 – Lipopolysaccharide;  
10 – Acetaminophen; 
11 – Electromyelogram; 
12 – Range of motion
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Abstract 
Objective. NSAIDs are commonly prescribed as treatment for inflammation, pain, and fever and 
work by inhibiting the synthesis of prostaglandins.  This review investigates whether the anti-
inflammatory actions of NSAIDs hinder muscle repair and strength gain after exercise-induced 
muscle injury (EIMI).  Methods.  This review was conducted using MEDLINE and PubMed 
databases.  Results.  NSAID use for the treatment of EIMI hinders satellite cell proliferation and 
skeletal muscle hypertrophy and repair, therefore blunting various benefits of eccentric exercise.  
Evidence supports short-term NSAID use both prophylactically and post-injury for its ability to 
reduce inflammation, lower serum creatine kinase levels, and reduce delayed-onset muscle 
soreness.  Use of NSAIDs past 28 days has not been investigated making long-term effects 
unclear.  Conclusion.  Clinically, short-term NSAID use is upheld as treatment for inflammation 
and pain following EIMI.  Athletes should recognize that NSAIDs inhibit muscle growth after 
EIMI.  Chronic users should be wary of unknown long-term effects of NSAIDs.  
 